Emgality® (Galcanezumab)

Para consultar la información para prescribir completa de Emgality® (Galcanezumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Was galcanezumab associated with blood pressure increases in clinical trials?

Treatment with galcanezumab did not result in hemodynamic changes consistent with vasoconstriction. The incidences of categorical or sustained increase in blood pressure at any time post baseline were similar between placebo and galcanezumab.

MX_cFAQ_GLC120_BP_INCREASE
MX_cFAQ_GLC120_BP_INCREASE
es-MX

Analysis of Blood Pressure Elevations

This medical response may not completely match the information in the current local labeling for GALCANEZUMAB. Please see local labeling for approved label information.

The cardiovascular adverse event profile of galcanezumab was evaluated using integrated data from a total of 5 placebo-controlled studies with up to 6 months of galcanezumab exposure (with 573.4 patient-years of exposure).1

Galcanezumab doses were pooled prior to the analysis, as galcanezumab doses were different across studies.1

In these studies, the majority of patients were female (>75%) and Caucasian (>75%), with a mean age of 41 to 42 years.2

Increases in blood pressure were evaluated as

  • categorical increases, or
  • sustained increases.2

This integrated analysis found that there were no significant differences between the galcanezumab and placebo groups in the frequency of

  • categorical increases in blood pressure, or
  • sustained increases in blood pressure.2

These findings are consistent with, and expand upon, an earlier analysis of cardiovascular safety based on data from 3 placebo-controlled studies which found that treatment with galcanezumab

  • did not result in hemodynamic changes consistent with vasoconstriction, and
  • did not increase the incidences of categorical or sustained increase in blood pressure at any time post baseline compared with placebo.3

Categorical Increases in Blood Pressure Similar to Placebo

Categorical blood pressure increases were defined as

  • treatment-emergent high ≥140 mm Hg with ≥20 mm Hg increase in systolic blood pressure, or
  • treatment-emergent high ≥90 mm Hg with ≥10 mm Hg increase in diastolic blood pressure.2

The percentages of patients with a categorical increase in systolic or diastolic blood pressure at any time post baseline were similar between treatment groups (Categorical Increases in Blood Pressure: Placebo-Controlled Group), and were not  affected by presence of elevated blood pressure at baseline.2 The difference in the percentage of patients between the placebo and galcanezumab groups was less than 1% in the safety population.

Categorical Increases in Blood Pressure:a Placebo-Controlled Group2

 

PBO

GMB Pooledb

Safety population

N=1582
n (%)

N=1580
n (%)

SBP

47 (3.0)

51 (3.2)

DBP

107 (6.8)

122 (7.7)

Safety population with elevated SBP or DBP at baseline

n/N (%)

n/N (%)

SBP

2/100 (2.0)

2/91 (2.2)

DBP

17/153 (11.1)

12/138 (8.7)

Abbreviations: DBP = diastolic blood pressure; GMB = galcanezumab; PBO = placebo; SBP = systolic blood pressure.

aCategorical increase in SBP was defined as treatment-emergent high ≥140 mm Hg with ≥20 mm Hg increase. Categorical increase in DBP was defined as treatment-emergent high ≥90 mm Hg with ≥10 mm Hg increase.

bAll galcanezumab doses combined.

Sustained Increases in Blood Pressure Similar to Placebo

Sustained blood pressure increases were defined as

  • elevation ≥140 mm Hg with ≥20 mm Hg increase in systolic blood pressure for 2 consecutive office visits, or
  • elevation ≥90 mm Hg with ≥10 mm Hg increase in diastolic blood pressure for 2 consecutive office visits.2

The percentages of patients with a sustained increase in systolic or diastolic blood pressure at any time post baseline were similar between treatment groups (Sustained Increases in Blood Pressure: Placebo-Controlled Group), and were not affected by the presence of elevated blood pressure at baseline.2 The difference in the percentage of patients between the placebo and galcanezumab groups was less than 1% in the safety population.

Sustained Increases in Blood Pressure:a Placebo-Controlled Group2

 

PBO

GMB Pooledb

Safety population

N=1537
n (%)

N=1544
n (%)

SBP

7 (0.5)

3 (0.2)

DBP

17 (1.1)

19 (1.2)

Safety population with elevated SBP or DBP at baseline

n/N (%)

n/N (%)

SBP

0/96 (0.0)

0/89 (0.0)

DBP

2/146 (1.4)

0/133 (0.0)

Abbreviations: DBP = diastolic blood pressure; GMB = galcanezumab; PBO = placebo; SBP = systolic blood pressure.

aSustained elevation in blood pressure was defined as elevation ≥140 mm Hg with ≥20 mm Hg increase in SBP for 2 consecutive office visits, or elevation ≥90 mm Hg with ≥10 mm Hg increase in DBP for 2 consecutive office visits.

bAll galcanezumab doses combined.

Postmarketing Reports of Adverse Events Related to Increased Blood Pressure

Postmarketing spontaneous reports in the Eli Lilly and Company spontaneous adverse events database through 27 March 2021 showed that

  • blood pressure increased and hypertension were rarely reported, and
  • blood pressure abnormal, blood pressure fluctuation, blood pressure diastolic increased, and blood pressure systolic increased were very rarely reported.4

Rarely reported is defined as an adverse event that has been reported at an estimated rate of ≥0.01% and <0.1% according to the reporting system information. Very rarely reported is defined as an adverse event that has been reported at an estimated rate of <0.01% according to the reporting system information.4

Postmarketing data do not necessarily represent the rate of occurrence of an adverse event in a treated population, but they represent a reporting rate of a particular adverse event to the company. Spontaneous reporting of adverse events can be highly variable and is not appropriately controlled clinical information on which to base an assessment of whether a particular drug product is the causal agent of an event.5

Spontaneous reporting has limited use due to

  • lack of control population
  • under-reporting or reporting bias, and
  • missing or incomplete information regarding medical history or concomitant medications.5

References

1Oakes T, Kovacs R, Rosen N, et al. Evaluation of cardiovascular risks in patients treated with longer-term exposure to galcanezumab. Neurology. 2021;96(15 Suppl):2344. https://n.neurology.org/content/96/15_Supplement/2344

2Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular risks in patients treated with longer-term exposure to galcanezumab. Poster presented at: 73rd American Academy of Neurology Meeting (AAN Virtual); April 17-22, 2021. Accessed May 5, 2021. http://lillyscience.lilly.com/download/6b3qbWdDjwtIwA2UzahuEp?utm_source=email&scannedLink=true.

3Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache. 2020;60(1):110-123. http://dx.doi.org/10.1111/head.13684

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

5Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(suppl 3):C40-C44. http://dx.doi.org/10.1016/S0149-2918(98)80007-6

Fecha de la última revisión: 2021 M06 05


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta